Mining the adenovirus virome for oncolytics against multiple solid tumor types

Cancer Gene Therapy

Volumn 18, Issue 10, 2011, Pages 744-750

  Chen, C Y ^a   Weaver, E A ^a   Khare, R ^a   May, S M ^a   Barry, M A ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

adenovirus; cancer; oncolytic

Indexed keywords

ONCOLYTIC ADENOVIRUS;

ADENOVIRUS; ADENOVIRUS 11; ADENOVIRUS 13; ADENOVIRUS 5; ADENOVIRUS 6; ADENOVIRUS B; ADENOVIRUS C; ADENOVIRUS D; ADENOVIRUS E; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; FEMALE; HAMSTER; HUMAN; HUMAN CELL; KIDNEY TUMOR; LIVER TUMOR; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; SEROTYPE; TUMOR XENOGRAFT;

ADENOVIRUSES, HUMAN; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CRICETINAE; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; HEK293 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PHYLOGENY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; CRICETINAE;

EID: 80052966552     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.47     Document Type: Article

References (24)

1. Davison AJ, Benko M, Harrach B. Genetic content and evolution of adenoviruses. J Gen Virol 2003; 84(Pt 11): 2895-2908. (Pubitemid 37336773)
2. Pereira HG, Kelly B. Dose-response curves of toxic and infective actions of adenovirus in HeLa cell cultures. J Gen Microbiol 1957; 17: 517-524.
3. Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211-1218.
4. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 1998; 101: 1013-1019. (Pubitemid 28248886)
5. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81: 4654-4663. (Pubitemid 46668663)
6. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996; 70: 6839-6846. (Pubitemid 26307395)
7. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713. (Pubitemid 28520834)
8. Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 2003; 7: 163-173. (Pubitemid 36395351)
9. Hoffmann D, Bayer W, Heim A, Potthoff A, Nettelbeck DM, Wildner O. Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma. J Invest Dermatol 2008; 128: 988-998. (Pubitemid 351374310)
10. Hoffmann D, Heim A, Nettelbeck DM, Steinstraesser L, Wildner O. Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma. Hum Gene Ther 2007; 18: 51-62. (Pubitemid 46105464)
11. Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D et al. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res 2009; 69: 5115-5125.
12. Shashkova EV, May SM, Barry MA. Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology 2009; 394: 311-320.
13. Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR, Barry MA. Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther 2010; 21: 179-190.
14. Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol 2009; 19: 165-178.
15. Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 2011; 17: 96-104.
16. Arnberg N, Edlund K, Kidd AH, Wadell G. Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 2000; 74: 42-48. (Pubitemid 30002881)
17. Burmeister WP, Guilligay D, Cusack S, Wadell G, Arnberg N. Crystal structure of species D adenovirus fiber knobs and their sialic acid binding sites. J Virol 2004; 78: 7727-7736. (Pubitemid 38915919)
18. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins avb3 or avb5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
19. Shashkova EV, Spencer JF, Wold WS, Doronin K. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther 2007; 15: 598-607.
20. Thomas MA, Spencer JF, Wold WS. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 2007; 130: 169-183.
21. Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, Shashkova EV et al. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther 2009; 16: 644-654.
22. Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D et al. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther 2009; 16: 625-637.
23. Weaver EA, Turner MA, Khare R, Borowski W, Barry MA. Characterization of human species C adenovirus serotype 6. Virology 2011; 412: 19-27.
24. Khare R, May SM, Vetrini F, Ng P, Weaver EA, Barry MA. Increased liver gene therapy by a Kupffer cell-evading adenovirus vector. Mol Ther 2011; 19: 1254-1262.